[Polatuzumab vedotin, bendamustine, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma, including the outcome as a bridging treatment to CAR-T cell therapy or allogeneic hematopoietic stem cell transplant]. - Physician's Weekly
SUBSCRIBE TO NEWSLETTERS


Advertisement

[Polatuzumab vedotin, bendamustine, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma, including the outcome as a bridging treatment to CAR-T cell therapy or allogeneic hematopoietic stem cell transplant].

Aug 07, 2023

ABOUT THE CONTRIBUTORS

  • Yuka Morita

    Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.

    Yu Yagi

    Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.

    Yusuke Kanemasa

    Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.

    Yuki Sasaki

    Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.

    Kento Ishimine

    Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.

    Yudai Hayashi

    Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.

    Mano Mino

    Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.

    An Ohigashi

    Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.

    Taichi Tamura

    Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.

    Shohei Nakamura

    Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.

    Toshihiro Okuya

    Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.

    Takuya Shimizuguchi

    Department of Radiation Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.

    Naoki Shingai

    Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.

    Takashi Toya

    Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.

    Hiroaki Shimizu

    Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.

    Yuho Najima

    Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.

    Takeshi Kobayashi

    Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.

    Kyoko Haraguchi

    Division of Transfusion and Cell Therapy, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.

    Noriko Doki

    Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.

    Yoshiki Okuyama

    Division of Transfusion and Cell Therapy, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.

    Kazuteru Ohashi

    Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.

    Tatsu Shimoyama

    Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.

REFERENCES & ADDITIONAL READING

PubMed

MORE ARTICLES BELOW

Physician’s Weekly Daily Brief

The latest articles and insights from your colleagues in your specialty(ies) of choice.

EXPLORE MORE

RECOMMENDED ARTICLES FOR YOU

ADVERTISEMENT

RECENT ARTICLES

PW PODCAST

MORE ARTICLES BELOW

Physician’s Weekly Daily Brief

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

RECOMMENDED ARTICLES FOR YOU

PW PODCAST